USE OF ANTI-CONNEXIN AGENTS FOR MODULATING THE THERAPEUTIC EFFECT OF PSYCHOTROPIC DRUGS

• US 20110172188A1
• Filed: 09/10/2009
• Published: 07/14/2011
• Est. Priority Date: 09/10/2008
• Status: Abandoned Application

• Current Assignee: Bio Modeling Systems OU Bmsystems
• Original Assignee: Bio Modeling Systems OU Bmsystems
• Inventors: Charveriat, Mathieu, Mouthon, Franck, Deslys, Jean-Philippe, Iris, Francois
• Application Number:
  US13/063,409
• Publication Number:
  US 20110172188A1
• Time in Patent Office: Days
• US Class Current: 514/64
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/135 having aromatic rings , e.g. ketamine, nortriptyline methadone A61K31/137
• CPC Class Codes: A61K 31/137 Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
• CPC Class Codes: A61K 31/165 having aromatic rings, e.g. colchicine, atenolol, progabide
• CPC Class Codes: A61K 31/196 the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
• CPC Class Codes: A61K 31/343 condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
• CPC Class Codes: A61K 31/4525 containing a five-membered ring with oxygen as a ring hetero atom
• CPC Class Codes: A61K 31/551 having two nitrogen atoms, e.g. dilazep
• CPC Class Codes: A61K 31/5513 1,4-Benzodiazepines, e.g. diazepam or clozapine
• CPC Class Codes: A61K 31/56 Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/18 Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The invention first relates to a product containing at least one connexin-blocking agent and a psychotropic drug as combination products for use simultaneously, separately, or spread over time in patients suffering from psychiatric and/or neurodegenerative disorders. The connexin-blocking agent is advantageously selected from the group comprising meclofenamic acid, 18-β-glycyrrhetinic acid, carbenoxolone, mefloquine, and 2-APB, and preferably consists of meclofenamic acid. The invention first relates to a product containing at least one connexin-blocking agent and a psychotropic drug as combination products for use simultaneously, separately, or spread over time in patients suffering from psychiatric and/or neurodegenerative disorders. The connexin-blocking agent is advantageously selected from the group comprising meclofenamic acid, 18-β-glycyrrhetinic acid, carbenoxolone, mefloquine, and 2-APB, and preferably consists of meclofenamic acid.

Claims

1-21. -21. (canceled)

22. Method for treating patients suffering from psychiatric and/or neurodegenerative disorders, including the administration to said patient of:

a) at least one psychotropic drug, and

b) at least one connexin-blocking agent,

in which said products a) and b) are administrated simultaneously, separately or spread out over time.

23. Method according to claim 22, characterized in that the connexin-blocking agent is chosen from the group including meclofenamic acid, 18-β

-glycyrrhetinic acid, mefloquine and 2-APB, and is preferably meclofenamic acid.

24. Method according to claim 22 or 23, characterized in that the psychotropic drug is a dopaminergic, GABAergic, adrenergic, acetylcholinergic, serotoninergic, opioidergic, adenosinergic, ionotropic, histaminergic, IMAO, Catechol-O-methyl transferase, DOPA decarboxylase or noradrenergic effector.

25. Method according to claim 24, characterized in that the psychotropic drug is a dopaminergic effector chosen from loxapine, acepromazine, methylphenidate, amantadine, pergolide, lisuride, bromocriptine, ropinirole, apomorphine, aripiprazole, sulpiride, amisulpride, sultopride, tiapride, pimozide, risperidone, haloperidol, penfluridol, zuclopenthixol or bupropion.

26. Method according to claim 24, characterized in that the psychotropic drug is a GABAergic effector chosen from tiagabine, topiramate, clorazepate, diazepam, clonazepam, oxazepam, lorazepam, bromazepam, lormetazepam, nitrazepam, clotiazepam, alprozolam, estazolam, triazolam, loprazolam, etifoxin, meprobamate, zopiclone, zolpidem, phenobarbital, felbamate or vigabatrine.

27. Method according to claim 24, characterized in that the psychotropic drug is an adrenergic effector chosen from dihydroergotamine, modafinil, adrafinil, mirtazapine or oxetorone.

28. Method according to claim 24, characterized in that the psychotropic drug is an acetylcholinergic effector chosen from sulbutiamine, tropatepin or trihexyphenidyl.

29. Method according to claim 24, characterized in that the psychotropic drug is a serotoninergic effector chosen from chlorpromazine, trimipramine, clozapine, olanzapine, cyamemazine, flupentixol, nefopam, fluvoxamine, clomipramine, sertraline, fluoxetine, citalopram, escitalopram, paroxetine, amitriptyline, duloxetine, venlafaxine, buspirone, carpipramine, zolmitriptan, sumatriptan, naratriptan, indoramine, ergotamine, ergotamine tartrate, pizotifene, pipamperone, methysergide, pizotyline, tianeptine, milnacipran, amitriptylene, trimipramine, viloxazine, tianeptine, hypericum and lithium.

30. Method according to claim 24, characterized in that the psychotropic drug is an opioidergic effector chosen from nalbuphine, buprenorphine, pethidine, codeine, tramadol, morphine, hydromorphone, oxycodone, methadone, dextropropoxyphene, meperidine, fentanyl, naltrexone or morphine hydrochloride.

31. Method according to claim 24, characterized in that the psychotropic drug is an adenosinergic effector chosen from carbamazepine or oxcarbazepine.

32. Method according to claim 24, characterized in that the psychotropic drug is an ionotropic effector chosen from flunarizine, ethosuximide, levetiracetam, lamotrigine, fosphenytoin or phenytoin.

33. Method according to claim 24, characterized in that the psychotropic drug is a histaminergic effector chosen from niaprazine, hydroxyzine or doxylamine.

34. Method according to claim 24, characterized in that the psychotropic drug is a monoamine oxidase effector chosen from moclobemide, selegiline or iproniazid.

35. Method according to claim 24, characterized in that the psychotropic drug is a catechol-O-methyl transferase effector chosen from entacapone or tolcapone.

36. Method according to claim 24, characterized in that the psychotropic drug is a DOPA decarboxylase effector chosen from benserazide or carbidopa.

37. Method according to claim 24, characterized in that the psychotropic drug is a noradrenergic effector such as mianserine, desipramine, moclobemide or bupropion.

38. Method according to claim 24, characterized in that the psychotropic drug is an effector acting on the limbic system, such as gabapentin or captodiamine.

39. Method according to claim 24, characterized in that the psychotropic drug is chosen from the group including clozapine, modafmil, paroxetine, diazepam, escitalopram, sertraline, venlafaxine and bupropion.

40. Method to potentiate the effect of a psychotropic drug in patients suffering from psychiatric and/or neurodegenerative disorders, by administering at least one connexin-blocking agent.

41. Method to reduce the doses of a psychotropic drug and/or to limit the adverse effects of a psychotropic drug, and/or to reduce the effects of failure and withdrawal to a psychotropic drug, in patients suffering from psychiatric and/or neurodegenerative disorders, by administering at least one connexin-blocking agent.